Looking Beyond BioNTech/Biotheus To Future Potential China Deals

Bispecifics/ADCs To Attract More Foreign Interest?

 
• By Xu Hu
  
What to expect next?
Bispecific antibody and antibody-drug conjugate in oncology will still be the popular targets for cross-border deals in 2025. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Focus On Asia